Summary

The outcome of patients with chronic lymphocytic leukemia treated with ibrutinib-based regimens indicates that complex metaphase karyotype is a more important predictor of outcome than del(17p). Lack of complex karyotype is associated with less-frequent disease progression. Patients with complex karyotype may be an ideal group in which to study novel treatments.